Oct10Mon

Member News from Almac Group

Almac Group Discover an Exciting Link between its Immune Response Assay and Checkpoint Inhibitor Based Therapy

Study Published in JNCI
Almac LogoCraigavon, N.I., 10 October 2016 – Almac Group’s Diagnostics business unit today announced the identification of a novel immune response mechanism in breast tumours deficient in DNA repair. The study has been published in the Journal of the National Cancer Institute (JNCI).The publication entitled ‘Activation of STING-Dependent Innate Immune Signalling By S-Phase-Specific DNA Damage in Breast Cancer’ follows on from Almac’s previous publication of a 44 gene immune based assay capable of prospectively identifying breast cancer patients with a defect in the FA/BRCA pathway who benefit from anthracycline based chemotherapy.

Read More
Oct04Tue

Member News from Almac Group

Almac Diagnostics Partner with ArcherDX 
Technology Offering Expanded to Include FusionPlex® and VariantPlex NGS Assays 
Almac LogoCraigavon, N.I., UK & Boulder, CO – 04 October 2016 – Almac Group’s Diagnostics business unit today announced its partnership with ArcherDx to provide FusionPlex® and VariantPlex NGS assays as part of their CDx partnership solutions.ArcherDX, the leader in NGS-based fusion detection assays and software, has also approved Almac Diagnostics as a Certified Service Provider (CSP) of Archer® NGS assays. This agreement further establishes Almac Diagnostics as a trusted partner providing scientific and technological excellence globally.Almac Diagnostics, the personalised medicine business unit of the Almac Group partners with Biopharma on the discovery, development and commercialisation of diagnostic tests including companion diagnostics.  It also has an internal portfolio of both prognostic and predictive assays in development across a wide range of disease areas. Read More
Sep23Fri

Member News: Congratulations Mike McGinn

Congratulations to Mike McGinn on his new position as Chief Marketing Officer for Chief Outsiders! 

Mike will be helping CEOs of small to midsize companies grow their businesses by providing my marketing and sales expertise on an interim or part time basis.

Sep23Fri

Member News from Almac Group

Almac LogoAlmac Group Celebrates 20 Years in North America with $5.2 million Expansion

Creation of 79 Additional Jobs in North Carolina

Craigavon, N.I., UK, – Tuesday 20 September 2016 Almac Group, the global contract development and manufacturing organisation, is celebrating 20 years in North America by announcing a $5.2 million investment and the creation of almost 80 new jobs across its Durham, North Carolina facilities.

Almac first established presence in the US in 1996 with the opening of its clinical trial operations in Audubon, Pennsylvania.  By 2000, Almac had expanded its North American presence into North Carolina through the acquisition of Applied Clinical Concepts Inc (ACCI) and Duke Clinical Research Institute Pharmacy (DCRIP) which merged to form Clinical Trial Services based in the Research Triangle Park, Durham.

“This latest investment and increase in capacity at our Durham facility is a sign of our continuing commitment to offer market driven solutions to our client base,” says Donna Christopher, Global VP Operations, Almac Clinical Services. We are delighted to mark our 20th year in the US with such a significant announcement – once again reinforcing our dedication to global expansion.”

Read More